AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Verastem Oncology Announces Positive Efficacy Data for Partner GenFleet Therapeutics' KRAS G12D Inhibitor VS-7375 in Advanced Non-Small Cell Lung Cancer.
ByAinvest
Wednesday, Aug 13, 2025 4:31 pm ET1min read
Verastem Oncology has announced positive data from partner GenFleet Therapeutics' Phase 1/2 study of GFH375 (VS-7375) in advanced non-small cell lung cancer. The study found an ORR of 68.8% at the recommended Phase 2 dose and 57.7% across all dose levels. The most common treatment-related adverse events were diarrhea, vomiting, nausea, and anemia. The data will be presented at the IASLC 2025 World Conference on Lung Cancer.
Verastem Oncology (Nasdaq: VSTM) has announced encouraging data from a Phase 1/2 study of GFH375 (VS-7375) in advanced non-small cell lung cancer (NSCLC). The study, conducted by partner GenFleet Therapeutics, demonstrated an overall response rate (ORR) of 68.8% at the recommended Phase 2 dose of 600 mg QD. Across all dose levels, the ORR was 57.7% in efficacy evaluable patients with NSCLC [1].The study, which included 142 patients, reported the most common treatment-related adverse events (TRAEs) as diarrhea, vomiting, nausea, anemia, decreased appetite, and neutropenia, predominantly Grade 1 or 2 in severity. TRAEs and severe adverse events (SAEs) occurred in 27.5% and 7.7% of patients, respectively, with no TRAE-related deaths reported [1].
The data will be presented in a mini oral presentation at the IASLC 2025 World Conference on Lung Cancer from September 6-9, in Barcelona, Spain [1].
Verastem Oncology is committed to developing new medicines for patients with RAS/MAPK-pathway-driven cancers. The company's pipeline includes novel small molecule drugs that inhibit critical signaling pathways in cancer, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition [1].
The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers. Verastem selected VS-7375 as its lead program in December 2023 and obtained a license for VS-7375 in January 2025 [1].
References:
[1] https://www.stocktitan.net/news/VSTM/verastem-oncology-announces-late-breaking-abstract-from-partner-gen-pydtctr7wr13.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet